Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit

W. Krajewski; M. Moschini; Ł. Nowak; S. Poletajew; A. Tukiendorf; L. Afferi; J. Teoh; T. Muilwijk; S. Joniau; A. Tafuri; A. Antonelli; A. Gozzo; A. Mari; E. Di Trapani; K. Hendricksen; M. Alvarez-Maestro; A. Serrano; G. Simone; S. Zamboni; C. Simeone; M. Marconi; R. Mastroianni; G. Ploussard; P. Rajwa; E. Laukhtina; A. Zdrojowy-Wełna; A. Kołodziej; A. Paradysz; K. Tully; J. Krajewska; R. Piszczek; E. Xylinas; R. Zdrojowy

Статья

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit

W. Krajewski, M. Moschini, Ł. Nowak, S. Poletajew, A. Tukiendorf, L. Afferi, J. Teoh, T. Muilwijk, S. Joniau, A. Tafuri, A. Antonelli, A. Gozzo, A. Mari, E. Di Trapani, K. Hendricksen, M. Alvarez-Maestro, A. Serrano, G. Simone, S. Zamboni, C. Simeone, M. Marconi, R. Mastroianni, G. Ploussard, P. Rajwa, E. Laukhtina, A. Zdrojowy-Wełna, A. Kołodziej, A. Paradysz, K. Tully, J. Krajewska, R. Piszczek, E. Xylinas, R. Zdrojowy,

2020

https://doi.org/10.3390/jcm9103306

BACKGROUND AND PURPOSE: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2-6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits. MATERIALS AND METHODS: Data from 645 patients with primary T1HG bladder cancer treated between 2001 and 2019 in 12 tertiary care centres were retrospectively reviewed. The study included patients who underwent reTURB before BCG induction (Pre-BCG group: 397 patients; 61.6%) and those who had reTURB performed after BCG induction (Post-BCG group: 248 patients, 38.4%). The decision to perform reTURB before or after BCG induction was according to the surgeon's discretion, as well as a consideration of local proceedings and protocols. Due to variation in patients' characteristics, both propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. RESULTS: The five-year recurrence-free survival (RFS) was 64.7% and 69.1% for the Pre- and Post-BCG groups, respectively, and progression-free survival (PFS) was 82.7% and 83.3% for the Pre- and Post-BCG groups, respectively (both: p > 0.05). Similarly, neither RFS nor PFS differed significantly for a five-year period or in the whole time of observation after the PSM and IPW matching methods were used. CONCLUSIONS: Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction.

Цитирование

Версии

1. Version of Record от 2020-10-15

Метаданные

Об авторах

W. Krajewski
Department of Urology and Oncologic Urology, Wrocław Medical University, 50-556 Wroclaw, Poland;, lllukasz.nowak@gmail.com, (Ł.N.);, anna.kolodziej@umed.wroc.pl, (A.K.);, romuald.zdrojowy@umed.wroc.pl, (R.Z.)
M. Moschini
Klinik für Urologie, Luzerner Kantonsspital, 6004 Lucerne, Switzerland;, marco.moschini87@gmail.com, (M.M.);, luca.afferi@gmail.com, (L.A.)
Ł. Nowak
Department of Urology and Oncologic Urology, Wrocław Medical University, 50-556 Wroclaw, Poland;, lllukasz.nowak@gmail.com, (Ł.N.);, anna.kolodziej@umed.wroc.pl, (A.K.);, romuald.zdrojowy@umed.wroc.pl, (R.Z.)
S. Poletajew
Second Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland;, slawomir.poletajew@cmkp.edu.pl
A. Tukiendorf
Department of Public Health, Wrocław Medical University, 50-556 Wrocław, Poland;, andrzej.tukiendorf@gmail.com
L. Afferi
Klinik für Urologie, Luzerner Kantonsspital, 6004 Lucerne, Switzerland;, marco.moschini87@gmail.com, (M.M.);, luca.afferi@gmail.com, (L.A.)
J. Teoh
S.H.Ho Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China;, jeremyteoh@surgery.cuhk.edu.hk
T. Muilwijk
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium;, tim.muilwijk@kuleuven.be, (T.M.);, steven.joniau@uzleuven.be, (S.J.)
S. Joniau
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium;, tim.muilwijk@kuleuven.be, (T.M.);, steven.joniau@uzleuven.be, (S.J.)
A. Tafuri
Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, 37129 Verona, Italy;, aletaf@hotmail.it, (A.T.);, alessandro_antonelli@me.com, (A.A.);, alessandraguro@gmail.com, (A.G.)
A. Antonelli
Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, 37129 Verona, Italy;, aletaf@hotmail.it, (A.T.);, alessandro_antonelli@me.com, (A.A.);, alessandraguro@gmail.com, (A.G.)
A. Gozzo
Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, 37129 Verona, Italy;, aletaf@hotmail.it, (A.T.);, alessandro_antonelli@me.com, (A.A.);, alessandraguro@gmail.com, (A.G.)
A. Mari
Department of Urology, Careggi Hospital, University of Florence, 50139 Florence, Italy;, andreamari08@gmail.com
E. Di Trapani
Department of Urology, European Institute of Oncology, 20143 Milan, Italy;, ettore.ditrapani@ieo.it
K. Hendricksen
Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands;, k.hendricksen@nki.nl
M. Alvarez-Maestro
Department of Urology Hospital Universitario La Paz, 28046 Madrid, Spain;, malvarezmaestro@hotmail.com, (M.A.-M.);, andrearodriguez.s@gmail.com, (A.R.S.)
A. Serrano
Department of Urology Hospital Universitario La Paz, 28046 Madrid, Spain;, malvarezmaestro@hotmail.com, (M.A.-M.);, andrearodriguez.s@gmail.com, (A.R.S.)
G. Simone
IRCCS “Regina Elena” National Cancer Institute, Department of Urology, 00144 Rome, Italy;, puldet@gmail.com, (G.S.);, riccardo.mastroianni@gmail.com, (R.M.)
S. Zamboni
Urology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia 25123, Italy;, stefania.zamboni@libero.it, (S.Z.);, csimeone@libero.it, (C.S.);, marconimariac86@gmail.com, (M.C.M.)
C. Simeone
Urology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia 25123, Italy;, stefania.zamboni@libero.it, (S.Z.);, csimeone@libero.it, (C.S.);, marconimariac86@gmail.com, (M.C.M.)
M. Marconi
Urology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia 25123, Italy;, stefania.zamboni@libero.it, (S.Z.);, csimeone@libero.it, (C.S.);, marconimariac86@gmail.com, (M.C.M.)
R. Mastroianni
IRCCS “Regina Elena” National Cancer Institute, Department of Urology, 00144 Rome, Italy;, puldet@gmail.com, (G.S.);, riccardo.mastroianni@gmail.com, (R.M.)
G. Ploussard
Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France;, g.ploussard@gmail.com
P. Rajwa
Department of Urology, Medical University of Silesia, 3 Maja Street 13-15, 41-800 Zabrze, Poland;, pawelgrajwa@gmail.com, (P.R.);, parady@poczta.onet.pl, (A.P.)
E. Laukhtina
Institute for Urology and Reproductive Health, Sechenov University, 119146 Moscow, Russia;, katyalaukhtina@gmail.com, Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, 1090 Vienna, Austria
A. Zdrojowy-Wełna
Department of Endocrinology, Diabetes and Isothope Therapy, Wroclaw Medical University, 50-556 Wroclaw, Poland;, aleksandra.zdrojowy-welna@umed.wroc.pl
A. Kołodziej
Department of Urology and Oncologic Urology, Wrocław Medical University, 50-556 Wroclaw, Poland;, lllukasz.nowak@gmail.com, (Ł.N.);, anna.kolodziej@umed.wroc.pl, (A.K.);, romuald.zdrojowy@umed.wroc.pl, (R.Z.)
A. Paradysz
Department of Urology, Medical University of Silesia, 3 Maja Street 13-15, 41-800 Zabrze, Poland;, pawelgrajwa@gmail.com, (P.R.);, parady@poczta.onet.pl, (A.P.)
K. Tully
Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, 44625 Herne, Germany;, karl.tully@elisabethgruppe.de
J. Krajewska
Department and Clinic of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, 50-556 Wroclaw, Poland;, wojciechowska.joan@gmail.com
R. Piszczek
Department of Urology and Oncologic Urology, Lower Silesian Specialist Hospital, 50-556 Wroclaw, Poland;, piszczek.radoslaw@gmail.com
E. Xylinas
Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, 75018 Paris, France;, evanguelosxylinas@hotmail.com
R. Zdrojowy
Department of Urology and Oncologic Urology, Wrocław Medical University, 50-556 Wroclaw, Poland;, lllukasz.nowak@gmail.com, (Ł.N.);, anna.kolodziej@umed.wroc.pl, (A.K.);, romuald.zdrojowy@umed.wroc.pl, (R.Z.)

Название журнала

Journal of Clinical Medicine

Том

Выпуск

Страницы

3306

Издатель

MDPI

Тип документа

journal article

Тип лицензии Creative Commons

CC BY

Правовой статус документа

Свободная лицензия

Источник

dimensions

Поиск по репозиторию

Статья

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit

Похожие публикации

Версии

Метаданные